Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M432Revenue (TTM) $M41.2Net Margin (%)-281.0Altman Z-Score-7.2
Enterprise Value $M474EPS (TTM) $-1.3Operating Margin %-238.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.6Pre-tax Margin (%)-281.0Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-17.1Quick Ratio3.4Cash flow > EarningsY
Price/Sales9.75-y EBITDA Growth Rate %19.3Current Ratio3.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-63.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M99.7ROIC % (ttm)-578.3Gross Margin Increase y-yN

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AGEN is held by these investors:



AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ARMEN GARO HChairman & CEO 2017-04-12Buy100,000$3.3529.25view
INCYTE CORP10% Owner 2017-02-14Buy10,000,000$6-27.83view
WIINBERG ULFDirector 2016-09-06Buy30,000$6.29-31.16view
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1836.16view
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1836.16view
Baysal OzerChief Business Officer 2016-05-05Buy2,250$3.139.68view
ARMEN GARO HChairman & CEO 2016-03-07Buy200,000$4.037.44view
ARMEN GARO HChairman & CEO 2015-12-29Sell219,576$4.59-5.66view
ARMEN GARO HChairman & CEO 2015-09-25Buy100,000$5.03-13.92view
Ballantyne Charles EvanCFO 2015-09-25Buy10,000$5.05-14.26view

Quarterly/Annual Reports about AGEN:

News about AGEN:

Articles On GuruFocus.com
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant Oct 20 2017 
GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from He Oct 13 2017 
Agenus to Present at Two Healthcare Investor Conferences In September Sep 19 2017 
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zos Sep 13 2017 
GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committe Sep 13 2017 
Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update Aug 03 2017 
Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow Jul 27 2017 
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine S Jun 21 2017 
Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant Jun 21 2017 
Agenus to Webcast Annual Meeting of Stockholders Jun 21 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK